David Sutton

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition

Aidan G. Gilmartin, Maureen R. Bleam, Arthur Groy et al. · Clinical Cancer Research · 2011 · 590 citations · Full text

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Steven D. Knight, Nicholas D. Adams, Joelle L. Burgess et al. · ACS Medicinal Chemistry Letters · 2010 · 367 citations · Full text

Highly Potent Inhibitor, Tumor Biology, Mammalian Target +16

Antitumor activity of an allosteric inhibitor of centromere-associated protein-E

Kenneth W. Wood, Latesh Lad, Lusong Luo et al. · Proceedings of the National Academy of Sciences · 2010 · 252 citations · Full text

Antitumor Activity, Cenp-e Motor Activity, Molecular Biology +18

Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture

M R Boyd, T. H. Bacon, David Sutton et al. · Antimicrobial Agents and Chemotherapy · 1987 · 238 citations

Viral Replication, Molecular Virology, Herpesvirus 1 +11

Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]

R. Anthony Vere Hodge, David Sutton, M R Boyd et al. · Antimicrobial Agents and Chemotherapy · 1989 · 210 citations · Full text

Pharmaceutical Science, Brl 42810, Pharmacotherapy +17